title: Treatment of pediatric Graves' disease is associated with excessive weight gain.
abstract: BACKGROUND
  Little information is available about changes in body weight and body mass index in children before, during, and after treatment for Graves' disease (GD).
  
  
  OBJECTIVE
  Our objective was to examine changes in body weight after treatment for GD in children as related to clinical features.
  
  
  METHODS
  The medical records of 43 pediatric patients with GD [35 girls and eight boys, aged 4.0-18.5 (mean 10.9) yr] were examined. Patients were included if clinical data were available for 1 yr before and after the diagnosis of GD.
  
  
  METHODS
  Weight, height, body mass index (BMI) z-scores, and thyroid hormone levels were assessed.
  
  
  RESULTS
  Overall, patients presented with an average BMI z-score of -0.02 ± 1.05 that was not different from the normal population (P = 0.921) or their premorbid values (P = 0.07). However, in the subset of patients who were initially overweight or obese in the premorbid state, the BMI decreased significantly during the development of hyperthyroidism (P < 0.05). After initiation of treatment, patients gained significant amounts of weight over the first 6 months leading to elevated BMI z-scores (P < 0.0001), and elevations in BMI persisted in about 25% of the patients.
  
  
  CONCLUSIONS
  Excessive weight gain within 6 months of treatment is seen in children treated for GD, and the gain in weight can persist.
authors.affiliation: Pediatric Endocrinology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
authors.forename: Nicole R
authors.initials: NR
authors.lastname: van Veenendaal
authors.forename: Scott A
authors.initials: SA
authors.lastname: Rivkees
mesh_terms: D000293:Adolescent; D000375:Aging / Q000502:physiology; D013956:Antithyroid Agents / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D001835:Body Weight / Q000502:physiology; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D006111:Graves Disease / Q000150:complications* / Q000628:therapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008713:Methimazole / Q000009:adverse effects; D011441:Propylthiouracil / Q000009:adverse effects / Q000627:therapeutic use; D012727:Sex Characteristics; D013960:Thyroid Function Tests; D013963:Thyroid Hormones / Q000097:blood; D013965:Thyroidectomy / Q000009:adverse effects; D015430:Weight Gain / Q000502:physiology*
chemical_list: D013956:Antithyroid Agents; D007457:Iodine Radioisotopes; D013963:Thyroid Hormones; D008713:Methimazole; D011441:Propylthiouracil